title: Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
abstract: Many regimens containing novel drugs have been developed for multiple myeloma (MM). It is not yet clear whether some of the novel agents are better than others. In a retrospective study, we have analyzed the outcomes of patients with first relapse of MM treated with thalidomide-based (T) regimens (n=105) or bortezomib-based (B) regimens (n=106). Both T and B groups were comparable regarding basic clinical parameters and first-line therapies. Combination of thalidomide with an alkylating drug (A) and dexamethasone (D) was used in 91 cases, T with D in five cases, and T alone in nine cases. A combination of bortezomib with A and D was used in 58 patients, B with D or A in 40 patients, and B alone in eight patients. In the T group, ORR was 51%, median TTP from the start of treatment for relapse of 13.1 months, and median OS of 30.4 months. In the B group, ORR was 50% with median TTP of 16.7 months and median OS of 37.2 months. No significant differences in ORR (p=0.774), TTP (p=0.207), or OS (p=0.889) were observed between the two groups. In conclusion, T- and B-based regimens appear to be equally effective in the treatment of first MM relapse.
authors.affiliation: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska 20, 625 00, Brno, Czech Republic. mkrejci@fnbrno.cz
authors.forename: Marta
authors.initials: M
authors.lastname: Krejci
authors.forename: Evzen
authors.initials: E
authors.lastname: Gregora
authors.forename: Jan
authors.initials: J
authors.lastname: Straub
authors.forename: Jiri
authors.initials: J
authors.lastname: Minarik
authors.forename: Vlastimil
authors.initials: V
authors.lastname: Scudla
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Adam
authors.forename: Andrea
authors.initials: A
authors.lastname: Krivanova
authors.forename: Ludek
authors.initials: L
authors.lastname: Pour
authors.forename: Lenka
authors.initials: L
authors.lastname: Zahradova
authors.forename: Tomas
authors.initials: T
authors.lastname: Buchler
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000517:prevention & control*; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone